328 related articles for article (PubMed ID: 10050695)
1. The role of low molecular weight heparin in total knee arthroplasty.
Iobst CA; Friedman RJ
Am J Knee Surg; 1999; 12(1):55-60. PubMed ID: 10050695
[TBL] [Abstract][Full Text] [Related]
2. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
3. Warfarin prophylaxis after total knee arthroplasty.
Lieberman JR
Am J Knee Surg; 1999; 12(1):49-53. PubMed ID: 10050694
[TBL] [Abstract][Full Text] [Related]
4. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
5. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
7. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
[TBL] [Abstract][Full Text] [Related]
8. DVT prophylaxis: better living through chemistry: affirms.
Pellegrini VD
Orthopedics; 2010 Sep; 33(9):642. PubMed ID: 20839678
[TBL] [Abstract][Full Text] [Related]
9. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
Whang PG; Lieberman JR
Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin for the prevention and treatment of venous thromboembolism.
Raskob GE
Curr Opin Pulm Med; 1996 Jul; 2(4):305-10. PubMed ID: 9363157
[TBL] [Abstract][Full Text] [Related]
11. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership.
Mesko JW; Brand RA; Iorio R; Gradisar I; Heekin R; Leighton R; Thornberry R
J Arthroplasty; 2001 Sep; 16(6):679-88. PubMed ID: 11547365
[TBL] [Abstract][Full Text] [Related]
13. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery.
Abad JI; Gómez-Outes A; Martínez-González J; Rocha E;
Arch Orthop Trauma Surg; 2007 Oct; 127(8):665-70. PubMed ID: 17089172
[TBL] [Abstract][Full Text] [Related]
14. [Prevention of pulmonary embolism].
Minar E
Acta Med Austriaca; 1992; 19(1):25-34. PubMed ID: 1316706
[TBL] [Abstract][Full Text] [Related]
15. Rationale for low-molecular-weight heparin prophylaxis after total knee arthroplasty.
Colwell CW; Hardwick ME
Clin Orthop Relat Res; 2006 Nov; 452():181-5. PubMed ID: 17016231
[TBL] [Abstract][Full Text] [Related]
16. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
17. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
18. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
[TBL] [Abstract][Full Text] [Related]
19. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. A meta-analysis of randomized trials.
Howard AW; Aaron SD
Thromb Haemost; 1998 May; 79(5):902-6. PubMed ID: 9609217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
